Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Penny M. Heaton"'
Autor:
Penny M. Heaton, Jeffrey S. Barrett
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 224-227 (2020)
Externí odkaz:
https://doaj.org/article/1c6d61eebd3146ada530a2bad48c3c8c
Autor:
Penny M. Heaton
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Six of the top ten leading causes of death in low resource settings could potentially be prevented by vaccination. Development of vaccines for individuals in these populations is difficult because of the biological complexity of the prevalent pathoge
Externí odkaz:
https://doaj.org/article/89910eb6504f4ea4b5cb8cf3dc2ba086
Autor:
Jintanat Ananworanich, Penny M. Heaton
Publikováno v:
Vaccines, Vol 9, Iss 9, p 961 (2021)
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTIs) in infants. Most deaths occur in infants under 3 months old, and those living in low and middle-income countries (LMICs). There are no maternal
Externí odkaz:
https://doaj.org/article/6c8a05d731534b14a8475f97388ac69b
Publikováno v:
Clinical Pharmacology & Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd1b1fcc3a14438066037bdbd8a607e4
https://doi.org/10.1002/cpt.2889
https://doi.org/10.1002/cpt.2889
Autor:
Penny M. Heaton
Publikováno v:
The Journal of Infectious Diseases. 224:931-933
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36cd0301e2f37ba47d7ca476a5a4d729
https://doi.org/10.1093/infdis/jiab234
https://doi.org/10.1093/infdis/jiab234
Autor:
Robin Mogg, Jintanat Ananworanich, Michael W. Dunne, Consuela Vera David, Heather Shih, Taryn Rogalski-Salter, Erika Gonzalez, Penny M. Heaton, Jeroen Medema, Mohamed Bassyouni, Jared Silverman
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Severe acute respiratory syndrome coronavirus 2 infection may be associated with a prothrombotic state, predisposing patients for a progressive disease course. We investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::276cd0583e2ff2349b59c82fb64ff0b7
https://pubmed.ncbi.nlm.nih.gov/34523673
https://pubmed.ncbi.nlm.nih.gov/34523673
Autor:
Alan H. Fairlamb, Elizabeth A. Winzeler, Graeme Bilbe, Mike Strange, Gagandeep Kang, Raquel Gabarró, Audra Halsey, David Barros, Félix Calderón, Valerie Mizrahi, Nicholas Cammack, Pauline Williams, Lluis Ballell, Penny M. Heaton, Carl Nathan
Publikováno v:
Nature Reviews Drug Discovery. 20:799-800
Tres Cantos Open Lab is a collaborative initiative that integrates teams from academia and GlaxoSmithKline to enable rapid testing of innovative therapeutic hypotheses for endemic infectious diseases. Here, we provide an overview of the key scientifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27a1e9cd9c8f911d64dc3a8c953bec7b
https://doi.org/10.1038/d41573-021-00143-2
https://doi.org/10.1038/d41573-021-00143-2
Autor:
Penny M, Heaton
Publikováno v:
The New England journal of medicine. 384(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c548712855c5f0742189831665ebabce
https://pubmed.ncbi.nlm.nih.gov/33503338
https://pubmed.ncbi.nlm.nih.gov/33503338
Autor:
Penny M. Heaton
Publikováno v:
New England Journal of Medicine
The New England Journal of Medicine
The New England Journal of Medicine
Leaving in its wake more than 12 million infections, over 550,000 deaths, and an economic toll in the trillions of dollars to date,1 the SARS-CoV-2 pandemic has devastated the most vulnerable in ou...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c248ddf32a1bc1d7c71654b439afb75
Autor:
Elena Netsi, Thea Norman, Ian Hudson, Dan Hartman, Trevor Mundel, Nick Cammack, Penny M. Heaton, Shawn Dolley
Publikováno v:
Gates Open Research
It is critical to ensure that COVID-19 studies provide clear and timely answers to the scientific questions that will guide us to scalable solutions for all global regions. Significant challenges in operationalizing trials include public policies for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79a0b36c148f1bdead73b4222eb372f0
http://europepmc.org/articles/PMC7324688
http://europepmc.org/articles/PMC7324688